INTRODUCTION
maxillary atrophy, 112.41±26.34
A double-blind clinical trial was conducted to examine the effect of concentrated growth factor (CGF), a new generation of platelet derivatives, on the healing outcome of maxillary sinus floor augmentation during maxillary sinus lift surgery. The study included 9 patients referred to the Tabriz University, Faculty of Dentistry, aged 30-80 years, with bilateral posterior partial edentulous or edentulous maxilla who underwent the procedure using a split-mouth technique. After lifting the Schneiderian membrane, bovine xenograft was randomly applied on one side (for example, left maxillary sinus) and CGF on the other side (for example, right maxillary sinus). Results from alizarin red and hematoxylin-eosin staining methods showed that the percentage of bone formed in the CGF group (112.41±26.34% and 96.16±24.49%, respectively) was significantly higher than in the control group (64.99±24.96% and 60.16±16.39%, respectively) (P<0.05). In addition, after 6 months, the amount of residual graft material in the control group (xenograft) was significantly higher than in the CGF group (P<0.05). These findings demonstrate that the use of CGF during open sinus lift surgery is reliable for the placement of dental implants.Recent advances in surgery, implants, and graft materials have enhanced the prognosis of implant treatments in the maxillary posterior area [Various grafting materials are applied for lifting the maxillary sinus floor, including autologous bone, xenografts, mineralized and demineralized bone allografts, and alloplasts [Compared to PRF, CGF fibrin matrices are larger, denser, and have a more robust network structure, making them more effective in increasing osteogenesis. In addition, CGFs are more cost-effective and can be supplied more quickly, increasing their appeal for use in sinus augmentation procedures [In one study on lifting the sinus floor by osteotomy technique using the CGF and placing short implants among patients with severe maxillary atrophy, Chen 